Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Regimen Shows Potential for Reducing TLS Risk in CLL

Jason Harris
Published: Tuesday, Jul 17, 2018

Kerry A. Rogers, MD

Kerry A. Rogers, MD
A brief course of treatment with obinutuzumab (Gazyva) and ibrutinib (Imbruvica) prior to venetoclax (Venclexta) significantly reduced tumor burden and the risk for tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL), according to results presented at the 2018 ASCO Annual Meeting.

, lead author Kerry Rogers, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discussed the feasibility of this regimen and what research still needs to be done with these agents in this patient population.

OncLive: What was the rationale for this study?

Rogers: This was an unplanned analysis in a prospective clinical trial. The trial was started a few years ago. The goal was to study 3 of the most effective drugs we had in CLL at the time, and they are still 3 of the most effective drugs that we have. They are all chemotherapy-free agents and have complementary mechanisms and nonoverlapping toxicity.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication